
Concord Drugs Ltd is Rated Sell by MarketsMOJO
2026-11-20 10:10:35Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 November 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Concord Drugs Ltd Valuation Shifts to Attractive Amid Mixed Market Returns
2026-11-16 08:00:59Concord Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters improve notably, shifting from very attractive to attractive. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point relative to peers and historical averages, warranting a closer examination of its price attractiveness and underlying fundamentals.
Read MoreConcord Drugs Gains 0.73%: Quarterly Surge Amid Mixed Market Returns
2026-11-14 16:04:13Key Events This Week Nov 09: Stock opens at Rs.72.72 with a 2.19% gain Nov 11: Price dips to Rs.71.11 amid lower volume Nov 12: Rebounds to Rs.72.95 with 2.59% gain Nov 13: Quarterly results released; closes at Rs.71.68 (-1.74%) Week OpenRs.71.16 Week CloseRs.71.68<div class="stat-change ...
Read More
Concord Drugs Ltd Reports Very Positive Quarterly Financial Performance Amid Mixed Long-Term Returns
2026-11-13 11:00:59Concord Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has delivered a very positive financial performance for the quarter ended September 2026, marked by robust revenue growth and margin expansion. Despite this, the company’s stock has experienced mixed returns relative to broader market indices, reflecting ongoing challenges and investor caution.
Read More
Concord Drugs Ltd is Rated Sell by MarketsMOJO
2026-10-26 10:10:39Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreConcord Drugs Ltd Falls 8.48%: Valuation Shift and Technical Upgrade Mark a Volatile Week
2026-10-10 16:05:08Key Events This Week 5 Oct: Valuation upgraded to Very Attractive amid market volatility 6 Oct: Investment rating upgraded from Sell to Hold on improved technicals 9 Oct: Week closes at Rs.70.40, down 8.48% Week OpenRs.76.92 Week CloseRs.70.40-8.48% <div class="stat-...
Read More
Concord Drugs Ltd Valuation Shifts to Very Attractive Amid Market Volatility
2026-10-05 08:01:58Concord Drugs Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite a mixed performance relative to the broader market. This change reflects evolving investor sentiment and a reassessment of the company’s price multiples compared to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.
Read More
Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals
2026-10-01 08:09:44Concord Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 30 Sep 2026. This revision reflects a complex interplay of deteriorating technical indicators, modest financial trends, valuation considerations, and overall quality assessments, despite the company’s recent impressive quarterly earnings.
Read More
Concord Drugs Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Improvements
2026-09-24 08:08:38Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold, reflecting notable improvements in technical indicators and robust quarterly financial performance. The pharmaceutical company’s recent results, combined with a stabilising technical trend and attractive valuation metrics, have prompted analysts to revise their outlook, signalling cautious optimism amid mixed long-term fundamentals.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
14-Nov-2026 | Source : BSENewsPaper publication of Financial results for quarter ended 30th Sep2026.
Financial Results For Quarter Ending 30Th Sep 2026.
12-Nov-2026 | Source : BSEBoard has approved and considered financial results for quarter ending 30th Sep 2026.
Board Meeting Outcome for Outcome Of Board Meeting For Quarterly Results
12-Nov-2026 | Source : BSEBoard has Considered and approved quarterly results for 30th Sep2026.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available